Puma Biotechnology (PBYI) Earnings Analysis

Puma Biotechnology (PBYI) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS -0.04 USD vs -0.13 USD est (+69.2%). It has beaten estimates in 5/5 recent quarters (100%). Trailing P/E 15.86.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does PBYI next report earnings?

No confirmed upcoming earnings date is currently scheduled for PBYI. This page updates as the calendar is published.

PBYI earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.04 USD-0.13 USD+69.2%Beat
2026-02-260.29 USD0.24 USD+20.8%Beat
2025-08-070.15 USD0.11 USD+36.4%Beat
2025-02-270.43 USD0.1 USD+330%Beat
2024-08-01-0.05 USD-0.1 USD+50%Beat

Beat rate: 5/5 (100%) over reported quarters with consensus data.

PBYI valuation and analyst view

Trailing P/E15.86
Trailing EPS0.47957 USD
Price / book3.12
Dividend yield0.00%
Market cap0.42B
Analyst consensusBuy (8 buy / 7 hold / 4 sell)

Related research pages

Frequently asked questions

When is Puma Biotechnology (PBYI)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for PBYI. This page updates as the calendar is published.

Did PBYI beat earnings last quarter?

In its 2026-05-07 report, PBYI posted EPS of -0.04 USD versus a -0.13 USD estimate — a beat of 69.2%.

What is PBYI's earnings track record?

Over the last 5 reported quarters with consensus data, PBYI beat estimates 5 times (100%).

What is PBYI's current P/E ratio and EPS?

PBYI trades at a trailing P/E of 15.86 on trailing EPS of 0.4795739532970021 USD.

What do analysts rate PBYI?

Analyst consensus is "Buy" across 19 ratings (0 strong buy, 8 buy, 7 hold, 4 sell, 0 strong sell).